• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    SC 13D/A 1 13da_20241122_hing_c_won.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

     

     

    HCW BIOLOGICS INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    40423R 105

    (CUSIP Number)

     

    Hing C Wong, Ph.D.

    HCW Biologics Inc.

    2929 N. Commerce Parkway

    Miramar, FL 33025

    (954) 842-2024

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 20, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     


    SCHEDULE 13D/A

     

    CUSIP No. 40423R 105

     

     

     

    (1)

    Names of reporting persons

    Hing C. Wong

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐        (b) ☐

    (3)

    SEC use only

     

    (4)

    Source of Funds (See Instructions)

     

    PF

    (5)

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     

    (6)

    Citizenship or Place of Organization

     

    United States of America

    Number of

    (7)

    Sole voting power

     

    11,926,537

    shares

    beneficially

    owned by

    (8)

    Shared voting power

      4,127,619(1)

    each

    reporting

    person

    (9)

    Sole dispositive power

    11,926,537

    with:

    (10)

    Shared dispositive power

       4,127,619(1)

    (11)

    Aggregate amount beneficially owned by each reporting person

       16,054,156(2)

    (12)

    Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

    ☐

    (13)

    Percent of class represented by amount in Row (11)

      36.04%(3)

    (14)

    Type of reporting person (see instructions)

    IN

     

     

    (1)

    Represents shares of Common Stock held in the joint names of Hing C. Wong, Ph.D., and his spouse, Ms. Bee Yau Huang.

     

    (2)

    Includes 4,127,619 shares of Common Stock held in the joint names of Hing C. Wong, Ph.D., and his spouse, Ms. Bee Yau Huang.

     

    (3)

    Percentage calculated based on 44,540,394 shares of common stock, par value $0.0001 per share, outstanding as of November 20, 2024, the closing date of the Company’s registered direct offering.

     

     

     

     


     

     

     

     

    SCHEDULE 13D/A

     

     

    This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Person on August 2, 2021, (the “Schedule 13D”) relating to the shares of common stock, no par value per share (the “Common Stock”), of HCW Biologics Inc., a Delaware corporation (the “Issuer”). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.

    Item 3. Source and Amount of Funds

    The Reporting Person used personal funds to acquire additional shares, in the amounts shown below, the securities of the Company.

     

    Securities

    Number of Shares #

    Amount Paid $

    Previously reported

    15,255,618

    $15,925,800

    Transaction 8/30/2021

    26,330

    $101,639.75

    Transaction 9/7/2022

    20,000

    $52,560.00

    Transaction 6/9/2022

    3000

    $6,800.00

    Transaction 6/13/2022

    1520

    $3,325.76

    Transaction 5/30/2023

    6,600

    $10,272.58

    Transaction 9/14/2023

    1,800

    $3,740.76

    Transaction 2/20/2024

    739,288

    $1,400,000.00

    Total

    16,054,156

    $17,504,139.00

     

    Item 5. Interest in Securities of the Issuer

    On November 20, 2024, HCW Biologics Inc. closed on a registered direct offering where it issued 4,160,000 shares of the Company’s common stock, par value $0.0001 per share, and pre-funded warrants to purchase up to 2,557,000 shares of common stock to a single institutional investor. On November 20, 2024, the institutional investor exercised all its pre-funded warrants and the Company issued 2,557,000 of registered Common Stock. This transaction decreased Reporting Person’s beneficial ownership as follows.

    (a)-(b) The Reporting Person has beneficial ownership of 16,054,156 shares of Common Stock. The percentage of beneficial ownership is approximately 36.04% of outstanding shares of Common Stock. The percentage of Common Stock is based on 44,540,394 shares of Common Stock as of November 22, 2024.

    The Reporting Person has the sole power to dispose or direct the disposition of all shares of Common Stock that the Reporting Person beneficially owned as of November 22, 2024, except for 4,127,619 shares of Common Stock which he shares the power to dispose or direct the disposition of with his spouse, Ms. Bee Yau Huang.

    (c) The Reporting Person has not effected any transactions in Common Stock in the last 60 days.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    The Reporting Person has entered into an agreement with the Company and the single institutional investor to which he has agreed not to sell, transfer, pledge or otherwise dispose of any of the shares of Common Stock for a period of 90 days after the date of the closing date of the registered direct transaction.

    Item 7. Material to be Filed as Exhibits.

    No exhibits to be filed.

    3

     


     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

     

     

     

     

     

    HCW BIOLOGICS INC.

     

     

     

     

    Date:

    November 22, 2024

    By:

    /s/ Hing C. Wong

     

     

     

    Hing C. Wong
    Founder and Chief Executive Officer

     

     


    Get the next $HCWB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on HCW Biologics with a new price target

      EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

      11/19/21 8:39:08 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

      Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Instituteon June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have success

      6/27/25 7:45:56 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

      MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied

      6/26/25 7:55:49 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

      MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitmen

      6/4/25 8:20:19 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    SEC Filings

    See more
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      7/1/25 8:30:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/26/25 8:00:29 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      6/23/25 4:40:38 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    See more
    • HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

      MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

      4/1/24 4:10:32 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

      SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

      11/22/24 4:53:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Financials

    Live finance-specific insights

    See more
    • HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

      MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

      8/12/22 7:00:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

      MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

      5/13/22 7:15:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care